JP2023513312A5 - - Google Patents
Info
- Publication number
- JP2023513312A5 JP2023513312A5 JP2022548653A JP2022548653A JP2023513312A5 JP 2023513312 A5 JP2023513312 A5 JP 2023513312A5 JP 2022548653 A JP2022548653 A JP 2022548653A JP 2022548653 A JP2022548653 A JP 2022548653A JP 2023513312 A5 JP2023513312 A5 JP 2023513312A5
- Authority
- JP
- Japan
- Prior art keywords
- aqueous composition
- composition according
- calcium
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026015698A JP2026074118A (ja) | 2020-02-13 | 2026-02-02 | ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976007P | 2020-02-13 | 2020-02-13 | |
| US62/976,007 | 2020-02-13 | ||
| US202163148105P | 2021-02-10 | 2021-02-10 | |
| US63/148,105 | 2021-02-10 | ||
| PCT/US2021/017880 WO2021163504A1 (en) | 2020-02-13 | 2021-02-12 | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026015698A Division JP2026074118A (ja) | 2020-02-13 | 2026-02-02 | ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513312A JP2023513312A (ja) | 2023-03-30 |
| JP2023513312A5 true JP2023513312A5 (cg-RX-API-DMAC10.html) | 2024-02-20 |
Family
ID=74858823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548653A Pending JP2023513312A (ja) | 2020-02-13 | 2021-02-12 | ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法 |
| JP2026015698A Pending JP2026074118A (ja) | 2020-02-13 | 2026-02-02 | ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026015698A Pending JP2026074118A (ja) | 2020-02-13 | 2026-02-02 | ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法 |
Country Status (18)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI917325B (zh) | 2019-06-04 | 2026-03-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | 能結合胸腺基質淋巴細胞生成素的抗體及其應用 |
| MX2023006596A (es) * | 2020-12-03 | 2023-06-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma. |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202529809A (zh) * | 2023-10-17 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗tslp抗體的醫藥組成物及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| EP3594356A1 (en) | 2009-11-04 | 2020-01-15 | Merck Sharp & Dohme Corp. | Engineered anti-tslp antibody |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| ES2964713T3 (es) * | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| CN107428828A (zh) | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| EA038332B1 (ru) | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| US10994011B2 (en) * | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| EP3609917A1 (en) * | 2017-04-12 | 2020-02-19 | Amgen Inc. | Treatment of asthma with anti-tslp antibody |
| MA48461A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| KR20200034748A (ko) * | 2017-07-27 | 2020-03-31 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Sost 항체 약학적 조성물 및 그의 용도 |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| WO2019178151A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| JP7719714B2 (ja) | 2018-10-15 | 2025-08-06 | アムジエン・インコーポレーテツド | ダンピング機構を有する薬物送達装置 |
| MA53913A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament |
| AU2020397170A1 (en) * | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
-
2021
- 2021-02-12 CR CR20220457A patent/CR20220457A/es unknown
- 2021-02-12 CN CN202180017163.9A patent/CN115279404A/zh active Pending
- 2021-02-12 CA CA3166964A patent/CA3166964A1/en active Pending
- 2021-02-12 AU AU2021219839A patent/AU2021219839A1/en active Pending
- 2021-02-12 KR KR1020227030979A patent/KR20220140772A/ko active Pending
- 2021-02-12 PE PE2022001741A patent/PE20230112A1/es unknown
- 2021-02-12 WO PCT/US2021/017880 patent/WO2021163504A1/en not_active Ceased
- 2021-02-12 EP EP21710162.5A patent/EP4103235A1/en active Pending
- 2021-02-12 UY UY0001039083A patent/UY39083A/es unknown
- 2021-02-12 US US17/760,427 patent/US20230078678A1/en active Pending
- 2021-02-12 JP JP2022548653A patent/JP2023513312A/ja active Pending
- 2021-02-12 BR BR112022016010A patent/BR112022016010A2/pt unknown
- 2021-02-12 PH PH1/2022/552050A patent/PH12022552050A1/en unknown
- 2021-02-12 IL IL295042A patent/IL295042A/en unknown
- 2021-02-12 MX MX2022010012A patent/MX2022010012A/es unknown
-
2022
- 2022-08-11 JO JOP/2022/0183A patent/JOP20220183A1/ar unknown
- 2022-08-12 CL CL2022002193A patent/CL2022002193A1/es unknown
- 2022-09-09 CO CONC2022/0012868A patent/CO2022012868A2/es unknown
-
2026
- 2026-02-02 JP JP2026015698A patent/JP2026074118A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7277681B2 (ja) | 抗体処方物 | |
| JP7267707B2 (ja) | 高濃度抗体製剤 | |
| JP2021100929A (ja) | 高純度および優れた収率の正確に折り畳まれたエタネルセプト | |
| US20060210557A1 (en) | Stabilized liquid polypeptide formulations | |
| KR20090021298A (ko) | 항-ｅｇｆｒ 항체의 동결건조 제제 | |
| CN106474470B (zh) | 一种抗il-17a抗体的组合物 | |
| JP2009526856A (ja) | 抗体製剤 | |
| JP2020079250A (ja) | ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体 | |
| CN110312505B (zh) | 包含肉毒杆菌毒素的稳定液体组合物 | |
| TW201325606A (zh) | 用氯化鈉穩定化之依那西普調配物 | |
| JP2023513833A5 (cg-RX-API-DMAC10.html) | ||
| JP2014533700A5 (cg-RX-API-DMAC10.html) | ||
| JP2022526799A5 (cg-RX-API-DMAC10.html) | ||
| EP3169709B1 (en) | Crystalline antibody formulations | |
| JP2024119827A (ja) | 抗ｉｌ１７ａ抗体の水性医薬組成物およびその使用 | |
| JP2020172526A (ja) | 結晶性抗体製剤 | |
| JP2023554087A5 (cg-RX-API-DMAC10.html) | ||
| JP2020511443A (ja) | 液体医薬組成物 | |
| WO2017055966A1 (en) | Low viscosity antibody compositions | |
| CN108602881A (zh) | 抗-因子d抗体制剂 | |
| JP2015536932A (ja) | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 | |
| JP7809117B2 (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 | |
| TW202426050A (zh) | 穩定抗體組合物 | |
| CN107205925B (zh) | 液体药物组合物 | |
| CA2726824A1 (en) | Protein formulation |